J9301 Obinutuzumab injection
Also known as: obinutuzumab, Gazyva
Injection of obinutuzumab, an anti-CD20 monoclonal antibody. Type II B-cell depleting antibody for lymphoma and chronic lymphocytic leukemia.
In Plain Language
lymphoma injection; B-cell cancer treatment
Clinical Context
Used for chronic lymphocytic leukemia with fludarabine and cyclophosphamide, and for follicular lymphoma with bendamustine.
RVU Information
CPT J9301 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9301?
CPT J9301 (Obinutuzumab injection) is a J Codes (Drugs) code. Injection of obinutuzumab, an anti-CD20 monoclonal antibody. Type II B-cell depleting antibody for lymphoma and chronic lymphocytic leukemia.
How is J9301 administered?
CPT J9301 is administered by a healthcare provider, typically via injection or infusion. Used for chronic lymphocytic leukemia with fludarabine and cyclophosphamide, and for follicular lymphoma with bendamustine. It is used by Oncology, Hematology, Internal Medicine.
When is CPT J9301 used?
Used for chronic lymphocytic leukemia with fludarabine and cyclophosphamide, and for follicular lymphoma with bendamustine.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.